Physicians face new contradictions in HIV care

Article Abstract:

Researchers discussed new developments in AIDS at the Ninth National AIDS Update. New drugs such as protease inhibitors are boosting T cell counts, but many patients are still susceptible to opportunistic infections. This occurs because the entire T cell repertoire may not be re-established. Many physicians are not sure when to start treatment with protease inhibitors. Early, aggressive treatment may prevent the virus from becoming resistant to the drugs. However, many patients may not be able to comply with the treatment for various reasons.

Risk factors, Opportunistic infections

---

Protease inhibitors bring new social, clinical uncertainties to HIV care

Article Abstract:

AIDS patients who take protease inhibitors may have trouble re-entering the work force. Protease inhibitors in combination with other AIDS drugs have reduced blood levels of HIV to undetectable levels and thereby prolonging patients' lives. However, many who were infected while young have no job skills. Treating AIDS as a chronic illness may disqualify them for disability benefits. Changes in laws may be required to allow AIDS patients to continue receiving disability payments while still protected by the Americans With Disabilities Act.

Laws, regulations and rules, Employment, HIV patients, Discrimination against AIDS virus carriers, HIV carriers discrimination

---

New HIV drugs cast in supporting roles

Article Abstract:

Non-nucleoside reverse transcriptase inhibitors appear to be very effective in treating early HIV infection when combined with other types of HIV drugs. Nevirapine is the first non-nucleoside drug to be approved by the FDA and research is continuing on loviride and delavirdine. Several studies have shown that nevirapine combined with AZT and ddI reduces viral levels in the blood as much as 96%. Substantial drops in viral levels have been seen in 80% of the patients taking the triple combination and the effect can last up to one year.

Evaluation, Drug therapy, Combination, Combination drug therapy, Enzyme inhibitors

Similar abstracts:

• Abstracts: Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS. Protease inhibitors
• Abstracts: The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. Genetic testing for cancer in children: short-term psychological effect
• Abstracts: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
• Abstracts: What's the point of ... lecturer practitioners? A steep learning curve for teachers. National Vocational Qualifications?
• Abstracts: Wrong focus for mammogram debate? Key may be improving compliance by older women. Proposal would stabilize funds for biomedical research

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.